CIK 0001597313
VRAY ViewRay, Inc.
Insider trading from SEC Form 4. Last filing Jun 30, 2023.
In brief
ViewRay, Inc. (VRAY) has 19 SEC Form 4 filings on file from 11 insiders, the latest filed on Jun 30, 2023. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
2 open-market trades have been scored at VRAY. The newest: James F. Dempsey (Chief Scientific Officer) sold $173k of stock on Mar 3, 2023, filed Mar 21, 2023, scored 11 (weak).
13 Form 144 notices of planned sales are on file, the latest filed Jul 25, 2023.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at ViewRay, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 11Weak | James F. Dempsey Chief Scientific Officer sell | $173k 42,000 shares | -6% | - | |
| 28Weak | Susan C Schnabel director buy | $117k 25,000 shares | +15% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jul 25, 2023 | EBRAHIMI FARHAD FRED 10% Stockholder | 7,899,190 4.31% of outstanding | $287k | Jul 24, 2023 | $2.7M |
| Jul 21, 2023 | JOHNSON B KRISTINE Director | 30,702 0.02% of outstanding | $1,598 | Jul 21, 2023 | $5,653 |
| Jul 21, 2023 | Prange Karen Director | 37,600 0.02% of outstanding | $2,256 | Jul 21, 2023 | $6,908 |
| Jul 20, 2023 | EBRAHIMI FARHAD FRED 10% Stockholder | 11,505,648 6.27% of outstanding | $690k | Jul 20, 2023 | none |
| Jul 20, 2023 | McCormack Robert S Officer | 310,683 0.17% of outstanding | $19k | Jul 20, 2023 | none |
| Jul 19, 2023 | Caley M. Castelein Director | 641,033 0.35% of outstanding | $57k | Jul 19, 2023 | none |
| Jul 19, 2023 | Caley Castelein Board Member | 1,545,600 0.84% of outstanding | $117k | Jul 19, 2023 | none |
| Jul 19, 2023 | Castelein Caley Director | 158,397 0.09% of outstanding | $11k | Jul 19, 2023 | none |
| Jul 19, 2023 | Prange Karen Director | 91,866 0.05% of outstanding | $6,908 | Jul 19, 2023 | none |
| Jul 19, 2023 | Ziegler Paul Jr Officer | 1,500 0.00% of outstanding | $104 | Jul 19, 2023 | none |
| Jul 19, 2023 | Ziegler Paul Jr Officer | 168,285 0.09% of outstanding | $12k | Jul 19, 2023 | none |
| Jul 18, 2023 | Drake Scott William Officer | 2,408,747 1.31% of outstanding | $165k | Jul 18, 2023 | none |
| Jul 18, 2023 | JOHNSON B KRISTINE Director | 79,622 0.04% of outstanding | $5,653 | Jul 18, 2023 | none |
Transactions
The newest 50 of 58 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise COMMON STOCKindirect: By Crescent River LLC | +20,700 | $4.00 | $83k | 7,998,400 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise COMMON STOCKindirect: By Crescent River LLC | +43,900 | $3.50 | $154k | 8,042,300 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise COMMON STOCKindirect: By Elstead 2020 GRAT | +15,300 | $3.50 | $54k | 897,700 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise COMMON STOCKindirect: By Havana 2020 GRAT | +24,800 | $4.00 | $99k | 504,500 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise COMMON STOCKindirect: By Shiraz Capital LLC | +131,400 | $4.00 | $526k | 6,745,038 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise PUT Option (Obligation to Buy)derivativeindirect: By Crescent River LLC | -20,700 | $0.00 | $0 | 1,281,100 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise PUT Option (Obligation to Buy)derivativeindirect: By Crescent River LLC | -43,900 | $0.00 | $0 | 1,237,200 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise PUT Option (Obligation to Buy)derivativeindirect: By Elstead 2020 GRAT | -15,300 | $0.00 | $0 | 102,300 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise PUT Option (Obligation to Buy)derivativeindirect: By Havana 2020 GRAT | -24,800 | $0.00 | $0 | 95,500 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise PUT Option (Obligation to Buy)derivativeindirect: By Shiraz Capital LLC | -31,400 | $0.00 | $0 | 243,600 | Jun 30, 2023 |
| Jun 28, 2023 | Farhad Fred Ebrahimi owner | XIn-the-money exercise PUT Option (Obligation to Buy)derivativeindirect: By Shiraz Capital LLC | -100,000 | $0.00 | $0 | 143,600 | Jun 30, 2023 |
| Jun 14, 2023 | Paul Ziegler Jr Chief Commercial Officer | FTax withholding Common Stock | -8,770 | $0.50 | $4,373 | 393,426 | Jun 16, 2023 |
| Jun 15, 2023 | Scott William Drake President & CEO | FTax withholding Common Stock | -116,003 | $0.48 | $56k | 4,000,362 | Jun 16, 2023 |
| Oct 24, 2022 | James F. Dempsey Chief Scientific Officer | FTax withholding Common Stock | -37,681 | $4.30 | $162k | 642,165 | Mar 21, 2023 |
| Mar 1, 2023 | James F. Dempsey Chief Scientific Officer | AGrant or award Common Stock | +86,405 | $0.00 | $0 | 728,570 | Mar 21, 2023 |
| Mar 1, 2023 | James F. Dempsey Chief Scientific Officer | FTax withholding Common Stock | -19,630 | $4.12 | $81k | 708,940 | Mar 21, 2023 |
| Mar 1, 2023 | James F. Dempsey Chief Scientific Officer | FTax withholding Common Stock | -14,872 | $4.12 | $61k | 694,068 | Mar 21, 2023 |
| Mar 2, 2023 | James F. Dempsey Chief Scientific Officer | FTax withholding Common Stock | -39,700 | $4.12 | $164k | 654,368 | Mar 21, 2023 |
| Mar 3, 2023 | James F. Dempsey Chief Scientific Officer | MOption exercise Common Stock | +42,000 | $0.75 | $32k | 696,368 | Mar 21, 2023 |
| Mar 3, 2023 | James F. Dempsey Chief Scientific Officer | SOpen-market sale Common Stock | -42,000 | $4.13 | $173k | 654,368 | Mar 21, 2023 |
| Mar 7, 2023 | James F. Dempsey Chief Scientific Officer | MOption exercise Common Stock | +125,000 | $0.75 | $94k | 779,368 | Mar 21, 2023 |
| Mar 1, 2023 | James F. Dempsey Chief Scientific Officer | AGrant or award Performance Unitsderivative | +86,405 | $0.00 | $0 | 86,405 | Mar 21, 2023 |
| Mar 3, 2023 | James F. Dempsey Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative | -42,000 | $0.75 | $32k | 292,305 | Mar 21, 2023 |
| Mar 7, 2023 | James F. Dempsey Chief Scientific Officer | MOption exercise Stock Option (right to buy)derivative | -125,000 | $0.75 | $94k | 167,305 | Mar 21, 2023 |
| Mar 1, 2023 | Robert S McCormack SVP Gen Counsel & Corp Sec | AGrant or award Common Stock | +86,405 | $0.00 | $0 | 558,363 | Mar 3, 2023 |
| Mar 1, 2023 | Paul Ziegler Jr Chief Commercial Officer | AGrant or award Common Stock | +115,207 | $0.00 | $0 | 448,499 | Mar 3, 2023 |
| Mar 1, 2023 | William P. Mr. Burke Chief Financial Officer | AGrant or award Common Stock | +103,686 | $0.00 | $0 | 356,318 | Mar 3, 2023 |
| Mar 1, 2023 | Scott William Drake President & CEO | AGrant or award Common Stock | +483,870 | $0.00 | $0 | 4,308,634 | Mar 3, 2023 |
| Mar 1, 2023 | Robert S McCormack SVP Gen Counsel & Corp Sec | FTax withholding Common Stock | -12,330 | $4.34 | $54k | 546,033 | Mar 3, 2023 |
| Mar 1, 2023 | Paul Ziegler Jr Chief Commercial Officer | FTax withholding Common Stock | -12,330 | $4.34 | $54k | 436,169 | Mar 3, 2023 |
| Mar 1, 2023 | William P. Mr. Burke Chief Financial Officer | AGrant or award Performance Unitsderivative | +103,686 | $0.00 | $0 | 103,686 | Mar 3, 2023 |
| Mar 1, 2023 | Scott William Drake President & CEO | FTax withholding Common Stock | -84,495 | $4.34 | $367k | 4,224,139 | Mar 3, 2023 |
| Mar 1, 2023 | Robert S McCormack SVP Gen Counsel & Corp Sec | FTax withholding Common Stock | -17,540 | $4.34 | $76k | 528,493 | Mar 3, 2023 |
| Mar 1, 2023 | Paul Ziegler Jr Chief Commercial Officer | FTax withholding Common Stock | -15,873 | $4.34 | $69k | 420,296 | Mar 3, 2023 |
| Mar 1, 2023 | Scott William Drake President & CEO | FTax withholding Common Stock | -70,453 | $4.34 | $306k | 4,153,686 | Mar 3, 2023 |
| Mar 2, 2023 | Scott William Drake President & CEO | FTax withholding Common Stock | -37,321 | $4.25 | $159k | 4,116,365 | Mar 3, 2023 |
| Mar 2, 2023 | Robert S McCormack SVP Gen Counsel & Corp Sec | FTax withholding Common Stock | -37,493 | $4.25 | $159k | 491,000 | Mar 3, 2023 |
| Mar 2, 2023 | Paul Ziegler Jr Chief Commercial Officer | FTax withholding Common Stock | -18,100 | $4.25 | $77k | 402,196 | Mar 3, 2023 |
| Mar 1, 2023 | Scott William Drake President & CEO | AGrant or award Common Stockderivative | +483,870 | $0.00 | $0 | 483,870 | Mar 3, 2023 |
| Mar 1, 2023 | Robert S McCormack SVP Gen Counsel & Corp Sec | AGrant or award Performance Unitsderivative | +86,405 | $0.00 | $0 | 86,405 | Mar 3, 2023 |
| Mar 1, 2023 | Paul Ziegler Jr Chief Commercial Officer | AGrant or award Performance Unitsderivative | +115,207 | $0.00 | $0 | 115,207 | Mar 3, 2023 |
| Jan 16, 2023 | William P. Mr. Burke Chief Financial Officer | AGrant or award Common Stock | +252,632 | $0.00 | $0 | 252,632 | Jan 17, 2023 |
| Jan 3, 2023 | Caley Castelein director | AGrant or award Common Stock | +16,590 | $4.40 | $73k | 898,477 | Jan 4, 2023 |
| Jan 3, 2023 | Scott William Drake President & CEO | FTax withholding Common Stock | -96,546 | $4.40 | $425k | 3,824,764 | Jan 4, 2023 |
| Jan 3, 2023 | Daniel Jeffrey Moore director | AGrant or award Common Stock | +26,363 | $4.40 | $116k | 353,872 | Jan 4, 2023 |
| Jan 3, 2023 | Susan C Schnabel director | AGrant or award Common Stock | +10,909 | $4.40 | $48k | 203,699 | Jan 4, 2023 |
| Jan 3, 2023 | Phillip M Spencer director | AGrant or award Common Stock | +12,727 | $4.40 | $56k | 155,029 | Jan 4, 2023 |
| Jan 3, 2023 | Gail R Wilensky director | AGrant or award Common Stock | +12,727 | $4.40 | $56k | 210,393 | Jan 4, 2023 |
| Nov 28, 2022 | Susan C Schnabel director | POpen-market purchase Common Stock | +11,366 | $4.71 | $54k | 179,156 | Nov 29, 2022 |
| Nov 28, 2022 | Susan C Schnabel director | POpen-market purchase Common Stock | +500 | $4.68 | $2,340 | 179,656 | Nov 29, 2022 |
50 of 58 rows shown.
Insiders
Everyone who has filed a Form 4 here.
- William P. Mr. BurkeChief Financial Officer
- Caley Casteleindirector
- James F. DempseyChief Scientific Officer
- Scott William DrakePresident & CEO
- Farhad Fred Ebrahimiowner
- Robert S McCormackSVP Gen Counsel & Corp Sec
- Daniel Jeffrey Mooredirector
- Susan C Schnabeldirector
- Phillip M Spencerdirector
- Gail R Wilenskydirector
- Paul Ziegler JrChief Commercial Officer
Questions about VRAY
Answered from the filings on this page, as of the latest one.
Are insiders buying VRAY?
No. In the last 90 days no insider at ViewRay, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade VRAY on the open market?
James F. Dempsey (Chief Scientific Officer) sold $173k of VRAY on Mar 3, 2023 and filed the Form 4 on Mar 21, 2023. InsiderTell scored 11 (weak).
How many insiders file Form 4 at ViewRay, Inc.?
11 people have filed a Form 4 at ViewRay, Inc., among them William P. Mr. Burke (Chief Financial Officer), Caley Castelein (director), James F. Dempsey (Chief Scientific Officer). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.